Filing Flows › Health Care › LifeMD (LFMD)
LifeMD (LFMD) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 5, 2026 · LifeMD (LFMD) Q2 2026 earnings results →
Q2 2026 Revenue down 4% year over year to $47.3M · 15¢ of every $1 of revenue lost · operating margin -15.1%
LifeMD made $47.3M in Q2 2026 (-4% Y/Y): Telehealth Subscription Revenue $29.3M, Telehealth $18.0M. Operating margin -15.1%, net loss $7.1M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $47.3M in Q2 2026, down 4% year over year and down 6% from the previous quarter. Telehealth Subscription Revenue was the largest line at 62% of revenue. Telehealth lost $2.0M year over year (down 10%), 115% of the total change.
Gross margin was 88.8%, up 2.8 points from Q2 2025. Operating costs exceeded revenue by $7.1M, an operating margin of -15.1%. Operating expenses grew 10% against a revenue fall of 4%. The fastest-growing cost line was Sales & marketing (+27%). The quarter ended with a net loss of $7.1M, narrower than the previous quarter's $8.9M loss.
Operating cash flow was −$6.9M. Non-cash charges added back $325K of depreciation and amortization and $790K of share-based compensation. Working capital and other items used $1.0M. Capital expenditures of $1.7M exceeded it, leaving free cash flow of −$8.6M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 5, 2026 | $47.3M | -4% | -15.1% | −$7.1M | −$6.9M |
| Q1 2026 | 10-Q | May 6, 2026 | $50.2M | -1% | -17.8% | −$8.9M | $445K |
| Q4 2025 | 10-K | Mar 10, 2026 | $7.1M | +29% | -87.9% | $19.9M | −$3.3M |
| Q3 2025 | 10-Q | Nov 17, 2025 | $60.2M | +13% | -3.3% | −$3.6M | −$147K |
| Q2 2025 | 10-Q | Aug 5, 2025 | $62.2M | +23% | -1.5% | −$1.6M | $8.6M |
| Q1 2025 | 10-Q | May 6, 2025 | $65.7M | +49% | 3.9% | $1.9M | $3.1M |
| Q4 2024 | 10-K | Mar 11, 2025 | $63.1M | +41% | 1.6% | $235K | $1.1M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About LifeMD
LifeMD is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. We believe the traditional healthcare model requiring patients to visit a physician’s office, travel to a retail pharmacy, and return for follow-up appointments or prescription refills is complex, inefficient, and costly which can discourage individuals from seeking necessary medical care and medications. At the same time, the United States (“U.S.”) continues to experience shortages in primary care key specialty areas.
In its own words, from its 10-K, filed Mar 10, 2026.
LifeMD against its Services-Offices & Clinics of Doctors of Medicine peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -4% against the peers' median -3%. Operating margin: -15.1% against the peers' median -12.9%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| LFMD LifeMD | Q2 2026 | $47.3M | -4% | -15.1% |
| HIMS Hims & Hers Health | Q2 2026 | $753M | +38% | -12.9% |
| TDOC Teladoc Health | Q3 2026 | $605M | -3% | -4.6% |
| STLN Starling Oncology | Q3 2026 | $170M | +24% | -1.8% |
| SBC SBC Medical Group Holdings | Q2 2026 | $49.2M | +13% | 38.5% |
| AIRS Airsculpt Technologies | Q3 2026 | $31.9M | -9% | -13.0% |
| CDIX Cardiff Lexington | Q2 2026 | $2.2M | -23% | -25.2% |
| HLYK HealthLynked | Q2 2026 | $250K | -58% | -215.7% |
Source: LifeMD 10-Q on SEC EDGAR · CIK 948320 · Services-Offices & Clinics of Doctors of Medicine
13F: who owns LFMD and who is buying
More on LFMD
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results